{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:54:16Z","timestamp":1789779256895,"version":"4.0.1"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1001\/jamacardio.2018.3476","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T20:15:29Z","timestamp":1540584929000},"page":"1090","source":"Crossref","is-referenced-by-count":35,"title":["A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention"],"prefix":"10.1001","volume":"3","author":[{"given":"George","family":"Thanassoulis","sequence":"first","affiliation":[{"name":"Preventive and Genomic Cardiology, McGill University Health Center, Montreal, Quebec, Canada"},{"name":"Mike and Valeria Rosenbloom Center for Cardiovascular Prevention, McGill University Health Center, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan D.","family":"Sniderman","sequence":"additional","affiliation":[{"name":"Preventive and Genomic Cardiology, McGill University Health Center, Montreal, Quebec, Canada"},{"name":"Mike and Valeria Rosenbloom Center for Cardiovascular Prevention, McGill University Health Center, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pencina","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"hoi180052r1","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"hoi180052r2","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample.","volume":"370","author":"Pencina","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi180052r3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1001\/jamacardio.2016.0991","article-title":"Risk of premature cardiovascular disease vs the number of premature cardiovascular events.","volume":"1","author":"Sniderman","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"3","key":"hoi180052r4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jacc.2017.11.007","article-title":"Cardiovascular risk and statin eligibility of young adults after an MI: Partners YOUNG-MI Registry.","volume":"71","author":"Singh","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi180052r5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamacardio.2017.2543","article-title":"The benefit model for prevention of cardiovascular disease: an opportunity to harmonize guidelines.","volume":"2","author":"Thanassoulis","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"16","key":"hoi180052r6","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1161\/CIRCULATIONAHA.115.018383","article-title":"Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease.","volume":"133","author":"Thanassoulis","year":"2016","journal-title":"Circulation"},{"issue":"24","key":"hoi180052r7","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1161\/CIRCULATIONAHA.108.816694","article-title":"Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study.","volume":"119","author":"Pencina","year":"2009","journal-title":"Circulation"},{"issue":"32","key":"hoi180052r8","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: 1. evidence from genetic, epidemiologic, and clinical studies. a consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"10","key":"hoi180052r9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk.","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"hoi180052r10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study.","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2706611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T22:26:27Z","timestamp":1542839187000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2018.3476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2018.3476","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}